Amgen, Inc. vs Allbirds Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Allbirds Inc trades at $2.6 (market cap $30.00M). The key difference: Amgen, Inc. is far larger — about 7471.3× Allbirds Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.
| AMGN | BIRD | |
|---|---|---|
Market Cap | $224.14B | $30.00M |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $16.99 |
52-Week Low | $271.18 | $2.21 |
Enterprise Value | $267.45B | $48.86M |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →